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Changes in Quality of Life Following Conversion From CyA to FK 506 
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ADV ANCES in immunosuppressive therapy have. al-lowed for improvements in both graft and patient 
survival. Nevertheless, rejection and adverse effects of 
immunosuppression continue to limit the effectiveness of 
organ transplantation. I FK 506 is a novel, potent immuno-
suppressive agent first used in clinical trials in early 1989.2 
The initial use of FK 506 was in liver transplant patients, 
with complications related to cyclosporine (CyA) use. 
Refractory rejection and other complications of CyA use, 
such as nephrotoxicity, severe hypertension, and steroid 
toxicity were indications for conversion to FK 506.3 While 
previous studies have demonstrated the effectiveness of 
FK 506, conversion in reversing some of the complications 
of CyA use, little is known about the effect of FK 506 
conversion on the quality of life of these patients. 
The aim of this study was to assess the quality of life of 
liver transplant patients before and after FK 506 conver-
sion. 
MATERIALS AND METHODS 
This was a retrospective study. The first 126 adult liver transplant 
patients who switched from CyA to FK 506 were included. The 
conversion occurred between the period March 1989 and Novem-
ber 1990. 
The mean age of our study population was 44.4 years (ages 16 
to 77). There were 70 females (55.5%) and 56 males (45.5%). 
Patients were on CyA for an average of 28.3 months before the 
switch. Data were collected an average of 15.5 months after 
conversion to assess FK 506's effect on quality of life issues. The 
reasons for conversion are shown in Table 1. 
The subjects were interviewed by telephone in June and July of 
1991. A standardized questionnaire was used. Open-ended ques-
tions were asked regarding side effects, including the worst side 
effects experienced while taking CyA compared to those experi-
enced with FK 506. The following question areas were addressed: 
1. Quality of life issues, including general health, work life, 
social activities, family life, and sex life. 
2. Specific side effects and reporting if they have improved, 
remained unchanged, or became worse. 
Table 1. Reaona for SwItch From CyA to FK 506 
RI8IOIl 
1. Ongoing rejection 
2. Renal failure 
3. CyA and/or steroid toxicity 
4. Hypertension 
No. of Patienta 
82 
30 
10 
4 
Pen:ent of Patients 
65.0 
23.8 
7.9 
3.2 
The majOrity of patients were switched 110m CyA to FK 506 because of 
refecIIon. The I8IT18ining patients were awi1I:hed due to renal failure. CyA and/or 
steroid toxicity, or hyperllln8ion. 
Interviewers were registered nurses specializing in clinical 
transplant research. These nurses were not involved in direct 
patient care and, therefore, blinded to any Cy A or FK S06 side 
effects experienced by the patients. 
RESULTS 
The patient's own assessment of hislher general health was 
the greatest determinant of our subject's quality oflife (Fig 
1). Sixty-three percent of our patients felt that FK 506 had 
improved their lives. Twenty-nine percent stated that they 
were unaffected by this switch in immunosuppression, and 
life became worse for 9% of our population. 
The effect of FK 506 on the ability to work and soci 
activities showed comparable results. An improved abilit) 
to work occurred in 43% of our subjects, whereas 48% 
were unchanged in work ability. Very few (9%) had 
decreased their working ability. Forty-eight percent of our 
subjects increased social activities, while 46% had no 
change. Only 6% reported a decline in their social activi-
ties. The biggest praise for FK 506 was a boost of energy 
after being switched. The biggest complaint was about 
tremors that interfered with accomplishing work. 
Family life and relationships, and sexual life shared 
similar results. Family life remained unchanged in 75% of 
our population. Twenty-one percent had improved their 
family life and 3% showed deterioration. Seventy-one 
percent of our subjects had unchanged sexual relation-
ships, followed by 20% reporting an improved sexual life 
Four percent of the study group had a decline in their 
sexual life, while 4% of the participants in the study 
preferred not to reply to this question. 
Patients who were interviewed reported numerous CyAJ 
steroid-related side effects prior to FK 506 conversion. By 
far, the mlijority of patients (101) noted side effects asso-
ciated with CyA use, which were endocrine-like in origin. 
The main endocrine side effect was hirsutism (Table 2). 
Seventy-seven subjects reported neurological distur-
bances, primarily tremors (Table 3). GI side effects were 
reported by 19 patients. The most frequent complaint was 
of nausea and abdominal cramps (Table 4). 
The response to FK 506 conversion was uniform. Sev-
enty-six percent of endocrine side effects. experienced on 
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Fig 1. Results after being switched from CyA to FK 506. 
Table 2. Endocrine Side Effects 
No. of Patients No. of Patients 
No. of Patients Improved on Unchanged on 
Symptom onCyA(%) FK506 (%) FK 506 (%) 
Hair growth 48(38) 45 (93.8) 3 (6.2) 
Hypertension 25 (20) 16 (64) 8 (32) 
Weight gain 15(11.9) 12 (80) 3 (20) 
Diabetes 13 (10.3) 4 (30.8) 6 (46.2) 
Table 3. Neurological Side Effects 
No. 01 Patients No. 01 Patients 
No. 01 Patients Improved on Unchanged on 
Symptom on CyA (%) FK506(%) FK506(%) 
Tremors 21 (16.6) 13 (61.9) 7 (33.3) 
Headache 11 (8.7) 8 (72.7) 2 (18.2) 
Mood swings 8 (6.3) 7 (87.5) 1 (12.5) 
Depression 7 (5.5) 6 (85.7) 1 (14.3) 
Insomnia 6 (4.8) 4 (66.6) 2 (33.3) 
Poor concentration 5 (4) 5 (100) 0 
Numbness/tingling sensation 5 (4) 4 (SO) 1 (20) 
Confusion 5 (4) 5 (100) 0 
Impaired memory 3 (2.4) 2 (66.6) 1 (33.3) 
Vision change 3 (2.4) 3 (100) 0 
Nervousness 3 (2.4) 2 (66.6) 1 (33.3) 
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Table 4. Gaatrolntestlnal Side Effects 
Symptom 
Nausea/abdominal cramps 
Anorexia 
Diarrhea 
No, of Patients 
onCyA (%) 
12 (9.5) 
4 (3.2) 
3 (2.4) 
Cy A, improved when switched to FK 506. This was also 
noted in 77% of neurological side effects and 63% of the 
gastrointestinal side effects. In contrast. a small percent-
age of patients complained of worsening side effects after 
FK 506 conversion; 13.5% complained of increased head-
aches. These were generally migraine-like in nature. Fine 
tremors, especially of the hands. were problematic with 
both CyA (16.6%) and FK 506 (12.7%). 
DISCUSSION 
This study suggests that the quality of life is improved in 
liver transplant patients after being converted from Cy A to 
FK 506. This was often identified by an improvement in 
general health. 
While many of the CyA side effects continued to plague 
the patients throughout Cy A therapy. most of the FK 506 
No. of Patients 
Improved on 
FK506 (%) 
6 (SO) 
3 (75) 
3 (100) 
No. of Patients 
Unchanged on 
FK 506 (%) 
4 (33.3) 
1 (25) 
o 
No. of Patients 
Worse on FK 
506(%) 
2 (16.7) 
o 
o 
side effects were experienced during the initial switch 
only. These occurred mainly during IV infusion. After 
being switched to oral FK 506, and after dose adjustments 
were made. many of the side effects resolved. Currently. 
we try to avoid IV dosing whenever patients can tolerate 
oral FK 506. 
It appears that FK 506 has improved quality of life, but 
a placebo effect cannot be ruled out. However, in general. 
it is our opinion that FK 506 has helped. 
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